
Sign up to save your podcasts
Or


This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.
By Sam and Karine4.8
193193 ratings
This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.

319 Listeners

506 Listeners

40 Listeners

122 Listeners

57 Listeners

3,360 Listeners

1,152 Listeners

188 Listeners

47 Listeners

517 Listeners

373 Listeners

51 Listeners

59 Listeners

51 Listeners

46 Listeners